Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 PRESS RELEASE - SIGA TECHNOLOGIES INC | kl03042_ex99-1.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 12, 2013
SIGA TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
0-23047
|
13-3864870
|
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission file number)
|
(I.R.S. employer
identification no.)
|
|
35 East 62nd Street
New York, New York
(Address of principal executive offices)
|
10065
(Zip code)
|
Registrant’s telephone number, including area code: (212) 672-9100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events.
On March 12, 2013, SIGA Technologies, Inc., a Delaware corporation (“SIGA”), issued a press release announcing the delivery of approximately 190,000 courses of its proprietary smallpox antiviral drug, Arestvyr™, to the United States Government’s Strategic National Stockpile. This delivery is the first of a series of deliveries of Arestvyr™ pursuant to SIGA’s contract with the Biomedical Advanced Research and Development Authority.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits
|
Exhibit No.
|
Description
|
|
99.1
|
Press Release, dated March 12, 2013
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SIGA TECHNOLOGIES, INC.
By: /s/ Daniel J. Luckshire
Name: Daniel J. Luckshire
Title: Chief Financial Officer
Date: March 13, 2013